Equities

Ribomic Inc

4591:TYO

Ribomic Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)84.00
  • Today's Change2.00 / 2.44%
  • Shares traded927.70k
  • 1 Year change-39.57%
  • Beta1.1863
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments3,4004,3254,702
Total Receivables, Net647160
Total Inventory2.272.072.41
Prepaid expenses40144144
Other current assets, total0.350.340.85
Total current assets3,5074,5424,908
Property, plant & equipment, net000
Goodwill, net------
Intangibles, net----0
Long term investments232323
Note receivable - long term------
Other long term assets111112
Total assets3,5474,5844,954
LIABILITIES
Accounts payable------
Accrued expenses121212
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total143187248
Total current liabilities156199261
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total--0.00--
Total liabilities156199261
SHAREHOLDERS EQUITY
Common stock64722238
Additional paid-in capital4,3485,3156,140
Retained earnings (accumulated deficit)(1020)(1653)(1684)
Treasury stock - common0.000--
Unrealized gain (loss)------
Other equity, total0.00--0.00
Total equity3,3914,3844,694
Total liabilities & shareholders' equity3,5474,5844,954
Total common shares outstanding363629
Treasury shares - common primary issue0.020.010
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.